跳至主要内容
临床试验/NCT02719405
NCT02719405终止2 期

A Prospective Randomized Controlled Trial to Evaluate the Effect of Infant Formula on the Resolution of Cow's Milk Allergy of Infancy

Massachusetts General Hospital4 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2016年2月最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
终止
入组人数
49
试验地点
4
主要终点
The percentage of subjects who develop tolerance to cow's milk protein by 12 months post randomization to study formula.

研究概览

简要总结

Primary Endpoint

-The percentage of subjects who develop tolerance to cow's milk protein by 12 months post randomization to study formula.

Secondary Endpoints

  • Tolerance

  • The transcriptional profile of milk-specific T cells by clinical outcome.

  • Growth and Weight Velocity

  • Stool Consistency and Frequency

  • The estimated frequency of milk-specific T cells by clinical outcome.

  • The TCR diversity of milk-specific T cells by clinical outcome.

  • The milk allergen component-specific IgE, IgG4 and IgA by clinical outcome.

  • Safety

  • The rate of reported adverse events by treatment group.

详细描述

Cow's Milk Allergy (CMA) is prevalent and most often presents during infancy. Disease manifestations vary through a range of immediate and delayed inflammatory responses to milk protein from anaphylaxis to enterocolitis. The natural history is also highly variable; most children will achieve clinical tolerance early in life, while a minority will have disease persisting to adulthood for reasons that are not known. Most presentations are mild and are managed by restriction or reduction of immunologically intact milk protein with reintroduction sometime after a year of age; however, there are data to suggest that some level of antigenic stimulation may be beneficial. Furthermore, recent data suggest that oral probiotic exposure may also promote tolerance, though the kinetics of tolerance acquisition, the interaction between these two factors (probiotics and milk antigen exposure) and their relationship to regulatory T cell responses are all poorly defined. Therefore, there is an unmet need to identify dietary interventions, along with corresponding immune responses, that favor the promotion of tolerance.

A major objective will be to measure the effect probiotics have on the development of tolerance to milk antigen over time. By following these infants during the first year of life, and repeatedly collecting blood and stool samples from them, we will be poised to analyze their stool microbiome signatures, and we will estimate the frequency, phenotype and TCR diversity of milk-specific T cells over time. By repeatedly challenging them with more immunologically intact milk protein, we will better define the kinetics of CMA resolution and its association to these variables. This information is likely to further elucidate CMA disease mechanisms and identify possible biomarkers of disease resolution versus persistence. It will be directly useful for evaluating the efficacy of probiotics and hydrolyzed formula for promoting milk tolerance.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
— 至 120 Days(Child)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Amino Acid Formula

Placebo Comparator

干预措施: Amino Acid Formula (Dietary Supplement)

EHCF

Active Comparator

Extensively Hydrolyzed Casein Formula

干预措施: Extensively Hydrolyzed Casein Formula (Dietary Supplement)

EHCF + LGG

Active Comparator

Extensively Hydrolyzed Casein Formula + Lactobacillus GG

干预措施: Extensively Hydrolyzed Casein Formula (Dietary Supplement)

EHCF + LGG

Active Comparator

Extensively Hydrolyzed Casein Formula + Lactobacillus GG

干预措施: Lactobacillus GG (Dietary Supplement)

结局指标

主要结局

The percentage of subjects who develop tolerance to cow's milk protein by 12 months post randomization to study formula.

时间窗: 12 months post randomization

次要结局

  • Tolerance as assessed by stool frequency.(36 months)
  • Safety as assessed by adverse events graded using the NCI-CTCAE scale by treatment group.(36 months)
  • Tolerance as assessed by the transcriptional profile of milk-specific T cells by clinical outcome.(36 months)
  • Tolerance as assessed by weight for age Z-scores.(36 months)
  • Tolerance as assessed by length for age Z-scores.(36 months)
  • Tolerance as assessed by weight for length Z-scores.(36 months)
  • Tolerance as assessed by stool consistency using the Bristol Stool Chart.(36 months)
  • Tolerance as assessed by the TCR diversity of milk-specific T cells by clinical outcome.(36 months)
  • Tolerance as assessed by changes in the stool microbiome.(36 months)
  • Tolerance as assessed by the estimated frequency of milk-specific T cells by clinical outcome.(36 months)
  • Tolerance as assessed by the milk allergen component-specific IgE, IgG4 and IgA by clinical outcome.(36 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Wayne G. Shreffler, MD, PhD

Principal Investigator

Massachusetts General Hospital

研究点 (4)

Loading locations...

相似试验